Erschienen in:
22.06.2017 | SAGES GUIDELINES
SAGES endoluminal treatments for GERD
verfasst von:
Jonathan Pearl, MD, Eric Pauli, MD, Brian Dunkin, MD, Dimitrios Stefanidis, MD, PhD
Erschienen in:
Surgical Endoscopy
|
Ausgabe 10/2017
Einloggen, um Zugang zu erhalten
Excerpt
Gastroesophageal reflux disease (GERD) is a common problem that affects approximately 30–40% of the adult population with at least 20% of Americans reporting weekly symptoms.1,2 GERD accounts for 8.9 million annual outpatient visits with an estimated annual cost of 24 billion dollars.2 For upper gastrointestinal endoscopy alone, the cost to the health care system is estimated at $12.3 billion annually.3 First-line therapy for GERD includes a combination of lifestyle modifications and medical therapy, with antireflux medications accounting for approximately $7.7 billion in annual US health care costs.4 GERD often requires lifelong treatment and is associated with serious health risks including esophagitis, esophageal stricture, Barrett’s, and adenocarcinoma of the esophagus. …